|Dr. Scott Koenig||CEO, Pres & Director||916.17k||635.2k||1952|
|Mr. James Karrels||Sr. VP, CFO & Sec.||546.76k||230.72k||1967|
|Dr. Ezio Bonvini||Sr. VP of Research & Chief Scientific Officer||593.39k||N/A||1954|
|Mr. Eric Blasius Risser||Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer||550.2k||453.39k||1973|
|Dr. Jon M. Wigginton||Sr. VP of Clinical Devel. & Chief Medical Officer||641.58k||77.49k||1962|
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3; MGA012, an anti-PD-1 monoclonal antibody, which inhibits programmed cell death protein 1 (PD-1); MGD013, a monoclonal antibody that targets the immune checkpoints PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing MGD009, a DART molecule that targets B7-H3 expressed on tumor cells and CD3; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD007, a DART molecule, which targets glycoprotein A33 and CD3; and MGD014, a DART molecule that targets virus-infected cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and Zai Lab Limited. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
MacroGenics, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 6. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 7; Compensation: 8.